论文部分内容阅读
手术和化疗是治疗上皮性卵巢癌的两大主要治疗手段,满意的肿瘤细胞减灭术是化疗成功的关键。上皮性卵巢癌复发率高达80%,化疗耐药是本病复发的根本原因。吉西他滨于2006年由美国食品药品监督管理局(Food and Drug Administration,FDA)批准用于停铂治疗半年后复发的卵巢癌患者的新化疗药物。本文聚焦该药近年来在上皮性卵巢癌中的应用及研究进展,现综述如下。
Surgery and chemotherapy are the two major treatments for epithelial ovarian cancer. Satisfactory cytoreductive surgery is the key to successful chemotherapy. Epithelial ovarian cancer recurrence rate as high as 80%, chemotherapy resistance is the root cause of recurrence of the disease. Gemcitabine was approved by the Food and Drug Administration (FDA) in 2006 as a new chemotherapeutic drug for patients with ovarian cancer who relapsed after six months of platinum-based treatment. This article focuses on the drug in epithelial ovarian cancer in recent years the application and research progress, are summarized below.